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INTRODUCTION
It is by now well documented that more than a third 
of patients with major depressive disorder (MDD) 
fail to respond to recommended pharmacologic and 
psychotherapeutic treatments.[1] Such patients may be 
appropriately termed as having “treatment resistant 
or refractory depression” (TRD). This condition 
necessitates the use of a more invasive therapy such as 
electroconvulsive therapy (ECT). ECT also produces a 
more rapid response than medications and psychotherapy, 
making ECT, especially useful in suicidal patients and 
nutritionally compromised patients where rapid response 
is essential.[2‑4] ECT may be superior to medications 
in more challenging cases where patients suffer from 
depression with psychotic features or catatonic features.[5] 
Finally, ECT is effective in psychotic and manic disorders 
and should be considered when first‑ and second‑line 
therapies for these conditions have not been effective or 
have only produced a partial response.[6] All of the above 
indications apply just as much in the geriatric population 
as in adults.
LITERATURE REVIEW
A PubMed and Google Scholar literature search was 
conducted with the terms “ECT,” “electroconvulsive 
therapy” and “geriatric or elderly after geriatric” for the 
time period between 2000 and 2017; the search yielded 
more than seventy unique studies which were reviewed.
Efficacy
ECT has been cited as effective in as many as 70%–80% 
of geriatric patients with MDD, independent of age, or any 
preexisting cognitive impairment.[7‑15] Existing evidence 
suggests that objective signs of response are supported by 
subjective report[16] and may be observed more quickly 
in the course of treatment.[17] One multisite study of 
253 patients of varying ages even reported that increasing 
age positively influenced response to treatment;[18] this 
possibility is reinforced by a relatively lower rate of 
rehospitalization in geriatric patients treated with ECT 
with respect to the nongeriatric population.[19] Although 
controversial, factors including temporal lobe atrophy (but 
not global atrophy),[20] cardiac vagal modulation,[21,22] and 
subcortical gray matter hyperintensity lesions[23,24] have 
been reported as biological factors potentially limiting 
efficacy and perhaps increasing mortality; a number of 
potential structural differences such as smaller temporal 
cortex and hippocampal volume have been identified as 
predictive of greater treatment response.[25,26] In addition, 
longer postictal recovery times have been associated 
with quicker response to therapy.[27] One larger study of 
239 geriatric patients indicated a lack of social support, 
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ABSTRACT
Electroconvulsive therapy (ECT) is an effective therapeutic intervention in the elderly patients with major depression, especially 
those with psychosis, suicidality, catatonia, nutritional compromise, and resistance to medications. Response rates can be as 
high as 80%. We present an extensive review of the relevant literature, provide a description of the ECT program at Virginia 
Commonwealth University in Richmond, Virginia, USA, and present results of our experience with ECT in fifty elderly patients. 
The treatments were safe, well tolerated, and produced high response rates, variably between 68% and 84%. Patients in the 
long‑term maintenance ECT program continue to show sustained benefits from ECT.
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poor self‑reported health rating, as well as the use of 
antipsychotic or antidepressant medications as predictors 
of longer time to remission whereas use of ECT in the past 
year was associated with shorter time to remission.[28] One 
possible mechanism proposed for the efficacy of ECT in 
geriatric patients was a relative increase in frontal lobe 
white matter identified by diffusion tensor imaging in 
eight depressed geriatric patients, ameliorating suspected 
problems in white matter integrity.[29]
Both right unilateral (RUL) and bifrontal (BF) lead 
placements have demonstrated strong efficacy in treating 
depression in the elderly.[30,31] High‑dose RUL ECT was 
demonstrated in one study to be more efficacious than 
bilateral ECT in a group of elderly patients after they had 
failed to improve on moderate dose RUL ECT.[31] To help in 
deciding whether to continue RUL or switch to BL therapy, 
one study proposed using electroencephalogram (EEG) 
indices as a guide for determining likelihood of benefit 
when RUL ECT appeared inadequate in an elderly 
cohort.[32] In the absence of definitive evidence, in our 
program, ECT is always started with RUL placement for 
MDD without psychosis – see program description below 
for more details on this.
Combination pharmacologic and ECT were shown to be 
more rapidly efficacious than monotherapy[33,34] in treating 
unipolar depression in the elderly with greater survival time 
and no apparent loss of tolerability.[35] This trend was also 
observed with combination therapy of psychotic depression 
in the maintenance phase.[36] Although evidence is relatively 
more sparse, ECT is reported to be effective in treating bipolar 
depression,[10] agitation in dementia patients,[37‑39] bipolar 
mania in dementia patients,[40‑42] catatonic schizophrenia,[43,44] 
and depression in multisystem atrophy.[45] Finally, due to 
significant rates of relapse in treating depression, maintenance 
combination therapy is recommended.[46] Maintenance ECT 
has been demonstrated to be effective in limiting relapse in 
patients with catatonic schizophrenia[47] as well as dementia 
with agitation and manic symptoms.[43]
Safety
Overall, ECT has been demonstrated to be relatively safe 
and well tolerated in the geriatric population,[9,11,33] and the 
incidence of adverse effects may be independent of age.[48] 
One study of 52 geriatric patients treated with ECT found 
that about twenty patients (38%) reported adverse effects 
including memory loss, confusion, and hypertension, 
suggesting a need for careful consideration of such factors 
when recommending ECT for geriatric patients.[8] Overall, 
cognitive deficits were the most commonly reported side 
effect of ECT ranging from 6% to 40% in nondemented 
elderly. These side effects were reported as transient or 
reversible,[10,18,49] and it has also been reported that cognitive 
function can be overall unaffected or may actually improve 
with ECT treatment over the longer term.[50‑52] No specific 
and reliable data are available on the prevalence of postictal 
delirious state in the elderly; in our own experience, 
this does happen rarely and quickly reverses. Ensuring 
hydration and normal electrolytes as well as avoiding 
long seizures or excessive sedating medication might help 
avoid this. RUL placement of electrodes has demonstrated 
fewer cognitive side effects.[53] Unlike in adults, no data are 
available on the relation between individual stimulation 
parameters such as electrical charge, frequency, pulse 
width, and energy delivered and cognitive side effects in 
the elderly. The same lack of data is also true for anesthetic 
and paralyzing agents. Neuropsychological assessment has 
shown both retrograde and anterograde deficits with the 
most common being delayed verbal anterograde memory.[50] 
More serious or life‑threatening adverse effects included 
an increased rate of falls[54] as well as increased incidence 
of bigeminy and trigeminy as well as supraventricular 
tachycardia[55,56] associated with treatment. Despite these 
potential risks, administration of ECT to patients with 
intracardiac defibrillators was determined to be safe 
by a number of studies.[51] Generally speaking, serious 
medical conditions become relative contraindications to 
ECT which can be overcome by the involvement of the 
appropriate consulting professionals.[57,58] In comparison 
with other modalities of treatment, one review pointed 
to prior results which indicated a relatively lower rate 
of side effects associated with ECT in comparison to 
pharmacotherapy in patients >75 years of age.[59] No 
difference in brain perfusion was detected between the two 
treatment modalities;[60] however, it has been noted that 
lower average pre‑ECT hemispheric cerebral blood flow 
and EEG mean signal has been associated with increased 
risk of developing dementia.[61]
Accessibility
Due to the medically intensive nature of the ECT procedure 
and longer periods of postprocedure observation, cost, 
and thus accessibility of treatment is a concern. Indeed, 
one European postal survey demonstrated that access was 
most frequently limited by cost.[62] One Canadian review of 
healthcare data of 12 million citizens indicated that ECT was 
more commonly prescribed in elderly patients with respect 
to other adults and that it remains a commonly prescribed 
treatment.[63] Perhaps paradoxically, reservations about 
utilization of ECT held by clinicians may also limit access 
as suggested by one study of geriatric psychiatrists in the 
Netherlands.[64] Decision‑making capacity does not appear 
to be a barrier to access overall, and psychoeducation 
is effective in further improving capacity;[65] however, 
there exists a threshold in cognitive functioning past 
which psychoeducation is ineffective in further improving 
decision‑making capacity.[66] The authors of the study 
opined that this limitation may be due to a ceiling effect 
and/or psychosis. Fear and social stigma associated with the 
treatment are significant barriers as well as limited access 
to psychiatric consultants and appropriately equipped 
facilities.[67] Animal‑assisted therapy may have a useful role 
in defraying the preprocedural anxiety and fear associated 
with ECT and improve access and adherence.[68] In this 
study conducted in our program, 15 min of interaction 
with a therapy dog while awaiting the ECT procedure 
significantly reduced fear and anxiety.
Although not directly relevant to this report, it is 
appropriate to briefly note that transcranial magnetic 
stimulation (TMS) is also a brain stimulation therapy 
applicable to TRD in the geriatric population but is more 
controversial from an efficacy standpoint; some studies 
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have suggested unambiguous efficacy[69,70] whereas others 
indicate an inverse relationship between age and efficacy, 
suggesting relatively lesser utility in the elderly.[71,72]
PROGRAM DESCRIPTION
The Department of Psychiatry at Virginia Commonwealth 
University Health System (VCUHS) provides a Brain 
Stimulation Therapy Program which includes clinical, 
educational, and research components. The clinical service 
is located within the medical psychiatry inpatient division 
and includes a dedicated ECT suite and four beds. Other 
components of this program not described here include 
TMS therapy located in a dedicated TMS therapy suite, 
vagal nerve stimulation therapy, ketamine infusion for 
depression in collaboration with anesthesiology, and a 
research program of deep brain stimulation for depression 
in collaboration with the Department of Neurosurgery.
Patients referred to the ECT program are from the entire 
Commonwealth of Virginia spanning approximately 
200 miles in width and 430 miles in length and a 
population of 8.5 million. Although the program at VCUHS 
is the largest in the Commonwealth, there are seven other 
programs offering ECT. In recent years, our program has 
been evaluating approximately 225 patients annually 
for ECT, 75% of which are outpatients. Typical inpatient 
referrals are for those with catatonia, psychotic depression, 
suicidality, and severe mania. About 175 of these eventually 
receive ECT. There are also approximately 25 patients 
receiving maintenance ECT annually. Between 20% and 
25% of all ECT patients are above the age of 65 years. Both 
inpatients and outpatients receive a standard evaluation 
focused on ECT by a senior consulting psychiatrist (AKP).
The ECT evaluation, in addition to standard psychiatric 
elements, focuses on verifying the primary diagnosis, 
prior treatment history both during the past and present 
episodes, specific factors that favor ECT including 
weight loss, electrolyte imbalance, suicidality, mood 
congruent delusions, and catatonia. Factors increasing 
risk are also carefully gathered and reviewed. For example, 
cardiomyopathy, low ejection fraction, pacemakers, 
bradycardia, risk of arrhythmia, and risk of aspiration 
and apnea. Depression is rated on the Montgomery–Asberg 
Depression Rating Scale (MADRS) on all patients.
Capacity to consent, surrogate consent in assenters without 
full capacity, and court permission for involuntary ECT 
are reviewed and implemented as appropriate. Logistics, 
schedule, transport, and supervision are especially reviewed 
for outpatients. All patients and significant others are shown an 
ECT video as well as provided with an ECT brochure, sample 
consent form, and outpatient safety instructions. Patients 
and family are encouraged to read the material and call back 
with any questions before the first treatment. Appropriate 
medical clearances are obtained as needed such as from 
a cardiologist or surgeon in patients who have undergone 
recent surgery. The minimum laboratory tests required 
before first ECT include complete hematology (complete 
blood count), comprehensive metabolic panel, and a 12‑lead 
electrocardiogram (EKG). Additional tests are ordered on as 
needed basis. Outpatients and a family member receive a 
one‑page outpatient ECT instruction sheet specifying taking 
nil per os after 12 midnight the night before ECT; taking 
morning medications with small sips of clear water; and 
seeking assistance of a responsible adult for transportation 
to and from the treatment session. Patients coming from 
other hospitals and nursing homes are expected to bring 
their complete medication list. Anticonvulsant medications, 
lithium, tricyclics, seizure‑enhancing medications such 
as clozapine and bupropion are reviewed for doses and 
regimens, and individualized instructions are provided on 
whether to hold the medication, reduce dose, or continue 
the medication. More caution is exercised before the first 
four treatments, and subsequent changes are made based 
on patient response and safety events.
The procedure staff consists of a faculty psychiatrist/
interventionist, two registered psychiatry nurses one of 
whom is in the treatment room, a psychiatry resident, a 
faculty anesthesiologist, and a certified registered nurse 
anesthetist (CRNA). Several other trainees may be present 
in the treatment room such as medical or nursing students. 
Significant others and family member are allowed to stay 
with patient until they are sedated. Pre‑ECT evaluation is 
conducted before every treatment and includes assessment 
of current complaints, update of psychiatric and medical 
history since initial evaluation, review of systems, physical 
examination, review of medications, and laboratory blood 
draws. The patient is examined separately by the resident or 
nurse practitioner, attending psychiatrist and anesthesiologist.
Once in the treatment suite, the patient is connected 
to various safety monitors including EEG, EKG, 
electromyogram (one limb), oximetry, CO2, tidal volumes, 
and blood pressure and heart rate. A time‑out is called 
and documented to verify patient identity, procedure, 
lead placement, and electrical charge. Typically, sedation 
is achieved with 1 mg/kg of methohexital and muscle 
paralysis with 1 mg/kg of succinylcholine/kg. Alternative 
sedatives include etomidate and propofol. Alternative 
muscle relaxants are nondepolarizing agents such as 
rocuronium and mivacurium. Prophylactic medications 
are administered as needed and are jointly decided by the 
anesthesiologist and psychiatrist. Commonly administered 
medications include labetalol for blood pressure control, 
ondansetron for nausea, ketorolac for pain, and ranitidine 
to reduce gastric acidity. Atropine or glycopyrrolate is not 
administered unless there is a specific indication such 
as history of extensive secretion in a prior treatment. 
Oxygenation is provided by the CRNA. Vital signs are 
continuously monitored including heart rate, blood 
pressure, heart rhythm, oxygen saturation, CO2, muscle 
activity in the left foot, and EEG. Upon obtaining sufficient 
sedation and muscle paralysis, electrical stimulation is 
administered through a Somatics, LLC, Thymatron IV 
machine. Electrode placement is determined initially by 
the psychiatric consultant who evaluates the patient, then 
on an ongoing basis by the psychiatrist/interventionist. 
Patients with MDD are typically started with RUL and 
brief pulse width of 0.5 ms and a charge based on the 
half‑age method. If necessary, the charge is titrated up 
at each treatment, to obtain a seizure of at least 25 s on 
the EEG. After 4 treatments, patients are reevaluated 
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and changed to BF placement if the progress is deemed 
insufficient. Patients with more pervasive pathologies 
including mania and catatonia are initiated with BF lead 
placement. Bitemporal (BT) lead placement is used if 
the first eight treatments (RUL × 4, BF × 4) for MDD) or 
four treatments (BF × 4 for psychosis) do not produce an 
adequate response, defined as 50% reduction in MADRS 
score or global improvement in psychosis/mania as judged 
by the treating psychiatrist. Caffeine benzoate 250 mg is Contd...
Figure 1: Contd...
ECT history, procedure and progress note ‑ VCUHS
Succinylcholine mg
Versed
Other
Seizure duration
Motor s
EEG s
Vital signs
Maximum HR
Maximum BP
Adverse events
None
Yes
If yes, describe
Other
Estimated blood loss
Specimen(s) removed
Comments
Changes for next ECT
Thymatron system settings/readings
Date EEG endpoint Sec
Time EMG endpoint Sec
Percentage energy set Percentage Base HR b/m
Charge delivered mC Peak HR b/m
Current A Average seizure 
energy index
µV2
Stimulus duration S Postictal 
suppression 
index
%
Frequency Hz Maximum 
sustained power
µV2
Pulse width ms Time to peak 
power
Sec
Static impedance Ohm Maximum 
sustained 
coherence
%
Dynamic impedance Ohm Time to peak 
coherence
s
Above thymatron system settings/readings were verified for accuracy 
with (name/title): _________________
Attending physician review, findings and plan
Condition at discharge from ECT recovery ECT service
Behavior
Orientation
Vital signs
Stable for D/C
Return date
ECT: Electroconvulsive therapy, YMRS: Young Mania Rating 
Scale,  MADRS: Montgomery Asberg Depression Rating Scale, GDS: Geriatric 
Depression Scale, MMSE: Mini‑Mental State Examination, VCUHS: Virginia 
Commonwealth University Health System, CGI: Clinician Global Index, EKG: 
Electrocardiogram, BT: Bitemporal, EEG: Electroencephalogram, HR: Heart rate, BP: 
Blood pressure, CNS: Central nervous system, NGT: Nitroglycerin, CGS: Clinician’s 
Global Scale, ROS: Review of Systems, HEENT: Head, Eyes, Ears, Nose, Throat
Figure 1: Electroconvulsive therapy procedure expandable e‑form
ECT history, procedure and progress note ‑ VCUHS
Name, DOB, MRN
Treatment number (index/maintenance)
Most recent consent date
Diagnoses (psychiatric)
Diagnoses (medical)
Rating scales (optional)
Befor 1st ECT: Complete the applicable scale of psychiatric 
symptoms (MADRS or GDS or YMRS) + MMSE and CGS
Every 4th ECT or every 4 weeks and after the last ECT: Complete the 
applicable scales and CGS/CGI
Insert rating scale here: Click on rubber stamp to insert appropriate 
rating scale
Psychiatric status
Note brief history, any changes since last ECT in symptoms, 
stressors, life situation (obtained from patient, escort, and record)
Medical status
At 1st treatment, note status pre‑ECT; then any changes since last 
treatment in symptoms, function, and new problems (ROS)
Focused physical exam
Vital signs
HEENT
Cardiac
Resp
Abdomen
CNS
Pain Pain score (0‑10)
Labs, EKG, radiology and other tests: Note baseline at 1st ECT; then 
any changes since last ECT
Current medications: Verified with patient, family or escort and most 
recent records
Psychotropics (include dose) Nonpsychotropics (list)
ECT treatment record ‑ VCU health system
Today’s treatment date
Today’s treatment time
Attending psychiatrist
Assistants
Description of procedure
Today’s treatment setting
Inpatient
Outpatient
Treatment course
Index (I) Treatment number
Maintenance (M) Treatment number
Electrode placement
Right unilateral (d’Elia)
BT
Left ant‑right temporal
Bifrontal
Medications administered: Include 
dose given
Lorazepam mg
Atropine mg
Caffeine mg
Esmolol
Etomidate
Glycopyrrolate
Ketorolac
Labetalol
Methohexital mg
NTG
Ondansetron
Propofol
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administered intravenously to those patients who exhibit 
a limited or no seizure in the prior treatment, 5 min 
before the planned electrostimulation. For postprocedure 
agitation, midazolam or lorazepam is used.
Except for the psychiatrist summary, documentation of the 
procedure occurs more or less contemporaneously in the 
electronic hospital record (Cerner Millennium) through 
conveniently located work stations. We have developed 
an ECT progress and procedure form into which all data 
are entered [Figure 1].
For patients with MDD, MADRS scores are recorded 
before initiating treatment, before every 4th treatment and 
upon the day of discharge from the ECT service. Adverse 
events are documented on the ECT procedure form. 
The faculty psychiatrist assesses progress in treatment, 
engages with families, and liaises with the primary 
treating psychiatrist throughout the ECT course and 
during maintenance ECT. Medication adjustments may be 
made by either the ECT psychiatrist or, when applicable, 
inpatient psychiatrist with electronic communication 
among the two as well as the patient and family. Typical 
modifications to pharmacologic management include 
withholding benzodiazepines; reducing the dosage or 
withholding of lithium and tricyclics; lowering or holding 
any antiseizure medication; reviewing doses of seizure 
enhancing medications (bupropion, clozapine, etc.); and 
administering medications to manage side effects such 
as pain and migraine medications. Cardiopulmonary and 
endocrine medications are not changed and are typically 
to be taken as usual on days of treatment. Insulin doses 
may be slightly increased during the course of ECT. 
Pacemakers are interrogated after each procedure by a 
cardiology technician. Anesthesiologists are responsible 
for airway and cardiovascular management until the 
patient successfully recovers from procedure.
Postprocedure, the patient is moved to a recovery area 
within the ECT suite with a registered nurse for 15–20 min 
during which there is continuous monitoring of vital 
signs, oxygenation, and orientation. Subsequently, the 
patient is moved to a room on the ECT unit and family 
members are invited to visit with the patient while the 
nurse continues checking vital signs, orientation, any 
complaints every 10–15 min for about 1 h. Patients who 
have received blood pressure lowering medications during 
the procedure may be observed for an additional hour 
to ensure there is no late drop in blood pressure. The 
intravenous (IV) access is maintained for all patients until 
released from the ECT Suite. Unless there is a specific 
medical indication, IV fluids or other medications are 
typically not ordered. However, in patients with catatonia 
as well as psychosis or depression with malnutrition, we 
do utilize the opportunity to provide hydration in the form 
of 750 mL of Ringer lactate or half normal saline over 6 h.
After ensuring that the vital signs are normal, orientation is 
consistently confirmed to self/time/place, and there are no 
acute complaints, the patient is released in the company of 
the escorting adult with the following instructions:
1. Mandatory: No driving or consuming alcohol 
for the day. Rest for 4 h. May engage in routine 
in‑house activities. No working at heights or with 
any type of machinery. No open flame cooking. 
Next day: Mild in‑house activities, if previously 
driving, then driving within neighborhood only with 
an accompanying person provided no medical or 
psychiatric symptoms including headache, dizziness, 
confusion, disorientation, chest discomfort, increased 
depression, suicidal thoughts, anxiety/panic, or 
hallucinations
2. Return to ECT with a responsible adult at a specified 
date and time
3. Medications: Individualized instructions
4. For any concerns or questions, the psychiatrist on‑call 
is available 24/7.
The typical ECT schedule for the elderly patient without 
any cognitive impairment unrelated to depression (e.g., 
dementia or mild cognitive impairment) or major medical 
conditions (e.g., congestive heart failure or arrhythmia) 
is three times weekly. For those with such comorbid 
impairments, the schedule is typically two times weekly. 
Very infrequently, we have utilized once a week treatment 
for logistical reasons (e.g., transport or accompanying 
provider schedule) or medical reasons such as a history 
of confusion with duration >8 h.
MATERIAL AND METHODS
For the analyses included within this report, 59 unique 
patients over 65 years of age were identified as receiving 
ECT at the VCUHS Brain Stimulation Unit during the 
years of 2015 and 2016. Within this group, nine patients 
are described separately as they received maintenance 
therapy during the study period; data for this report were 
collected by review of the charts of the fifty patients by 
the first author (ADS). We gathered information on age, 
gender and racial distribution, number of treatments, 
placement of electrodes, charge administered, as well 
as subjective and objective indicators of outcome. We 
reviewed each procedure note for documentation of any 
adverse events. These included reported side effects by 
patients and families, observations made by the treatment 
team, and depression treatment scales (primarily MADRS) 
administered during the course of treatment.
RESULTS
Analyses were conducted on the fifty patients who 
received index or cluster treatments. Index treatment 
course is typically 10–12 treatments in length provided 
for a full episode of major depression or psychosis. Cluster 
treatment is a shorter course of 4–6 treatments in length 
and was provided for a partial relapse of symptoms, during 
the maintenance phase.
The average age was 71.6 ± 5.2 years. There were 
24 males and 26 females. Thirty‑three received index 
and 17 received cluster treatments. The most common 
psychiatric diagnosis was MDD (n = 36, 72%) followed 
by bipolar disorder (n = 13, 26%) and schizoaffective 
disorder (n = 1, 2.0%). The average number of treatments 
received was 10.
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Overall, by report of patients and families, 42 out of 
50 patients (84% of respondents) were significantly 
improved. The psychiatrist determined that 48 out of 
50 patients showed some degrees of improvement in 
the target symptoms (96%). Using a modified 5‑point 
Clinician Global Index, where −1= decline/worsening 
of symptoms; 0 = no change; 1 = minimal improvement; 
2 = moderate improvement; and 3 = high/substantial 
improvement, psychiatrist determined average score 
was 1.98 ± 0.78. Thirty‑four (68%) patients showed 
moderate or higher improvement. Paired initial and 
final MADRS scores were available however, for only 
21 patients (42% of the sample); average initial scores 
were 28.2 ± 9.5 and final scores were 14.9 ± 7.8. The 
paired t‑test result suggested a significant improvement 
after treatment (n = 21, t = 6.792, P < 0.001). Side 
effects associated with treatment were common including 
short‑term memory loss (n = 15, 30%), headache (n = 11, 
22%), transient cognitive impairment (n = 7, 14%), other 
central nervous system complaints (e.g., dizziness, fatigue, 
and irritability; n = 3, 6%), other pain (n = 2, 4%), and 
nausea (n = 2, 4%). Serious adverse events were not 
seen except in one case with transient bigeminy and 
sustained bradycardia requiring prolonged monitoring 
and cardiology consultation (n = 1, 2%).
The nine patients receiving maintenance ECT included 
five females and four males, with an average age of 
72 years. Indications included MDD (n = 3), MDD with 
psychosis (n = 2), bipolar depression (n = 3), and atypical 
psychosis (n = 1). The number of maintenance ECT 
sessions received ranged from 2 to 90 with an average of 
27 treatments during the maintenance phase, typically 
administered once a month. All of these patients maintained 
a moderate or higher level of improvement and hence 
M‑ECT is being continued. Patients were taking various 
medications at the time of treatment which were managed 
by their own primary psychiatrist.
DISCUSSION
Our data appear to be consistent with findings in the 
literature in the sense that both subjective (82.3%) 
and objective (96%, mild improvement or better and 
68%, moderate or better) improvement in depressive 
symptomatology appear to be on the order of the 
benefit reported elsewhere in the literature. Our data 
demonstrate significant overall reported improvement of 
about 50% in depressive symptomatology as measured 
by the MADRS during the index course. Incidence of 
side effects and adverse effects was also similar to[8] or 
lower than[9] reported in the literature. In the absence of 
any mortality or serious adverse events, our experience 
strongly argues for considering ECT in the treatment of 
the elderly in the treatment sequence of TRD. Although 
cognitive impairment is typically seen in 30% of the 
patients (literature and our experience), this has not proven 
to affect the patient’s quality of life (QOL) significantly or 
resulted in lasting impairment. It should be noted that we 
did not use an extensive battery of neuropsychological tests 
or specific QOL scales which might have revealed more 
subtle impairments.
The strengths of the program include a structured 
organization of personnel with a physician as director (AKP) 
and a team of dedicated professionals to oversee all aspects 
of the program including quality, safety, regulatory and 
legal, human rights, patient selection, and outcome as well 
as the fiscal aspects. The thorough evaluation of referred 
patients from all over the Commonwealth of Virginia 
ensures verification of diagnosis and indication for ECT 
and procedures for appropriate consent, education of 
patient and significant other, and preparation for ECT. The 
follow‑through by team members ensures compliance with 
visits, management of safety, adjustment in treatment plan, 
measurement of outcomes, and assistance with follow‑up 
care. The thorough documentation allows for review and 
ongoing quality improvement. The program has received 
many accolades including a recent major donation from a 
grateful patient/family for training students and staff in ECT.
There are, however, several weaknesses to the program 
and the results reported here. In particular, capacity 
is limited by space and staff and wait periods can be 
4 weeks long in nonurgent cases. One hour observation 
may not be sufficient. While fortunately there is no 
documented instance of a serious adverse event during 
the immediate hours after discharge, it may be prudent 
to extend the observation time to 2 h. Assessment of 
cognition is currently conducted by clinical judgment and 
administration of the Mini–Mental Status Examination; 
more sophisticated neuropsychological assessment may 
reveal subtler abnormalities. There is only anecdotal 
information on relapse after ECT without any formal 
monitoring.
The results reported here are from a program review for 
quality purposes and not a formal research study. They are 
susceptible to contamination and bias from factors that are 
not controlled such as concomitant therapies including 
medication, counseling, and varying levels of care (family, 
hospital, nursing home, etc.). Minor adverse effects such 
as transient agitation, headache, muscle soreness, and 
psychological complaints such as discomfort with the 
oxygen mask and paralysis before complete sedation are 
not strictly documented.
Numerous opportunities exist for improving our program 
as well as filling the gaps in the literature. By no means 
comprehensive or exhaustive, an arbitrary list of opportunities 
from a programmatic and service perspective includes (i) 
encouraging ECT programs to implement uniform assessment 
procedures, (ii) maintain a database and contribute data to a 
registry, and (iii) enhancing access to education for providers 
on the efficacy and safety of ECT in the elderly. From a formal 
research perspective, conducting studies on topics such as (i) 
use of RUL versus BL in nondepressed elderly patients such 
as those with catatonia and other psychotic disorders, mania, 
and agitation associated with dementia and (ii) efficacy of 
different schedule of ECT in the elderly using biweekly and 
triweekly schedules.
CONCLUSIONS
The literature and our experience strongly support the 
efficacy and safety of ECT in geriatric patients; however, 
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there are some factors unique to this population which beg 
further consideration when recommending this modality 
of treatment. A few examples have been mentioned above. 
Could the biological differences in brain tissue conductivity 
be corrected by the use of medical interventions such 
as preprocedure hydration, use of caffeine, or other 
stimulants? Perhaps improvements such as this and others 
mentioned in this manuscript could further improve the 
efficacy of ECT. Some authors noted that neurotropic 
effects of ECT may underlie its therapeutic benefit. 
Combined therapy with pharmacologic intervention 
along with brain stimulation was determined to be more 
effective than monotherapy, and maintenance therapy 
has demonstrated efficacy in limiting relapse. A variety 
of disorders including bipolar depression, dementia with 
severe agitation, mania, and schizophrenia may also be 
responsive to ECT.
Maximization of benefit and minimization of memory 
loss and other side effects through sequential RUL, then 
BF, and then BT placement is consistent with the adult 
population. ECT is accepted as a safe treatment modality 
even for patients with implanted implantable cardioverter 
defibrillators and other general medical problems after 
consultation with the appropriate specialists; however, 
the possibility of increased rate of falls, especially on the 
day of ECT, as well as induction of arrhythmias during 
and immediately after the procedure must be considered 
when clearing elderly patients for ECT. Accessibility 
is limited primarily not only by cost but also negative 
public perception in the United States. Controversies 
about capacity to consent and protection of human 
rights, the inherent challenges of involuntary ECT, as 
well as unfounded fears about disrupting the brain and 
mind through electrical stimulation likely result in the 
underutilization of ECT. Provider education is an important 
tool in enhancing access and referral; psychoeducation 
maximizes capacity to consent but may be difficult with 
patients suffering from comorbid psychosis or dementia. 
The viability of TMS as an alternative to ECT in the 
geriatric population continues to be evaluated.
Through an examination of the existing literature on this 
topic as well as a preliminary analysis of data gathered from 
our program at VCUHS, we advocate for the appropriate 
utilization of ECT when treating geriatric patients suffering 
from TRD and other refractory psychotic and manic 
conditions.
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